Composition for transmucosal administration containing conenzyme Q as the active ingredient
View Patent ↗The present invention relates to the supply of coenzyme Q which is highly useful in maintaining human health, and provides a method and preparations whereby coenzyme Q can be efficiently supplied to patients having difficulties in oral administration, aged having swallowing difficulties and patients with diseases caused by topical disorders. It is found that the coenzyme Q concentration in the blood or topical mucosae can be elevated by using a composition for transmucosal administration containing oxidized coenzyme Q and/or reduced coenzyme Q as the active ingredient, wherein the total content of the oxidized coenzyme Q and the reduced coenzyme Q amounts to 0.0001 to 99% by weight of the whole composition.
1. A method for transferring coenzyme Q into a living organism, comprising applying a composition comprising, as an active ingredient, reduced coenzyme Q represented by formula (2), or, a mixture of oxidized coenzyme Q represented by formula (1) and reduced coenzyme Q represented by formula (2) to a mucosa which is the intestine, the nasal mucosa, the otic mucosa or the vaginal mucosa:
(wherein n represents an integer of 1 to 12)
(wherein n represents an integer of 1 to 12),
wherein the total content of oxidized coenzyme Q and reduced coenzyme Q is 0.0001 to 99% by weight of the whole of the composition and the proportion of reduced coenzyme Q relative to the total amount of oxidized coenzyme Q and reduced coenzyme Q exceeds 20 wt %.
2. A method according to claim 1 , wherein the oxidized coenzyme Q represented by formula (1) is oxidized coenzyme Q 10 , and the reduced coenzyme Q represented by formula (2) is reduced coenzyme Q 10 .
3. A method according to claim 1 , wherein the proportion of reduced coenzyme Q relative to the total amount of oxidized coenzyme Q and reduced coenzyme Q exceeds 20 wt %.
4. A method for increasing the amount of coenzyme Q in a mucosa,
comprising applying a composition comprising, as an active ingredient, reduced coenzyme Q represented by formula (2), or, a mixture of oxidized coenzyme Q represented by formula (1) and reduced coenzyme Q represented for formula (2) to the mucosa which is the intestine, the nasal mucosa, the otic mucosa or the vaginal mucosa:
(wherein n represents an integer of 1 to 12)
(wherein n represents an integer of 1 to 12),
wherein the total content of oxidized coenzyme Q and reduced coenzyme Q is 0.0001 to 99% by weight of the whole of the composition and the proportion of reduced coenzyme Q relative to the total amount of oxidized coenzyme Q and reduced coenzyme Q exceeds 20 wt %.
5. A method according to claim 4 , wherein the oxidized coenzyme Q represented by formula (1) is oxidized coenzyme Q 10 , and the reduced coenzyme Q represented by formula (2) is reduced coenzyme Q 10 .
6. A method for treating a disease selected from the group consisting of hemorrhoid, an intestinal disease, allergic rhinitis, pollinosis and conjunctivitis,
comprising applying to a subject having the disease a composition comprising, as an active ingredient, reduced coenzyme Q represented by formula (2), or, a mixture of oxidized coenzyme Q represented by formula (1) and reduced coenzyme Q represented by formula (2) to a mucosa:
(wherein n represents an integer of 1 to 12)
(wherein n represents an integer of 1 to 12),
wherein the total content of oxidized coenzyme Q and reduced coenzyme Q is 0.0001 to 99% by weight of the whole of the composition and the proportion of reduced coenzyme Q relative to the total amount of oxidized coenzyme Q and reduced coenzyme Q exceeds 20 wt %.
7. A method according to claim 6 , wherein the oxidized coenzyme Q represented by formula (1) is oxidized coenzyme Q 10 , and the reduced coenzyme Q represented by formula (2) is reduced coenzyme Q 10 .
8. A method according to claim 6 , wherein the mucosa is the intestine, the nasal mucosa, the otic mucosa or the vaginal mucosa.
9. A formulation for transmucosal administration for treating a disease selected from the group consisting of hemorrhoid, an intestinal disease, allergic rhinitis, pollinosis and conjunctivitis comprising, as an active ingredient, reduced coenzyme Q represented by formula (2), or, a mixture of oxidized coenzyme Q represented by formula (1) and reduced coenzyme Q represented for formula (2):
(wherein n represents an integer of 1 to 12)
(wherein n represents an integer of 1 to 12),
wherein the formulation is selected from the group consisting of a suppository, nose drops, ear drops, eye drops, an oral mucosal applicator, a troche, an electuary, a vaginal suppository and a toothpaste,
and the total content of oxidized coenzyme Q and reduced coenzyme Q is 0.0001 to 99% by weight of the whole of the composition and the proportion of reduced coenzyme 0 relative to the total amount of oxidized coenzyme Q and reduced coenzyme Q exceeds 20 wt %.
10. A formulation according to claim 9 , wherein the oxidized coenzyme Q represented by formula (1) is oxidized coenzyme Q 10 , and the reduced coenzyme Q represented by formula (2) is reduced coenzyme Q 10 .
11. A formulation according to claim 9 , further comprising a medicinal ingredient other than oxidized coenzyme Q represented by formula (1) and reduced coenzyme Q represented by formula (2).
12. A formulation according to claim 9 , which is a suppository, and wherein the content of coenzyme Q is not less than 30 mg and not more than 100 mg.
13. A method according to claim 9 , which is eye drops or nose drops, and wherein the content of coenzyme Q is 0.01% to 10% by weight.